A Phase 2, Randomized, Double-blind, Placebo-controlled, Fixed-dose, Parallel-group, Multicenter, Efficacy, and Safety Study of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis

Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled, Fixed-dose, Parallel-group, Multicenter, Efficacy, and Safety Study of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2016

At a glance

  • Drugs Nalfurafine (Primary)
  • Indications Pruritus
  • Focus Therapeutic Use
  • Sponsors Mitsubishi Tanabe Pharma Corporation; Toray Industries
  • Most Recent Events

    • 25 Feb 2015 Status changed from completed to discontinued, as reported by ClinicalTrials.gov.
    • 05 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top